Mesenchymal stem cell therapy for liver disease: full of chances and challenges.

Published on Oct 27, 2020in Cell & Bioscience5.026
· DOI :10.1186/S13578-020-00480-6
Xue Yang13
Estimated H-index: 13
Yan Meng3
Estimated H-index: 3
+ 3 AuthorsChen Zong9
Estimated H-index: 9
Liver disease is a major health problem that endangers human health worldwide. Currently, whole organ allograft transplantation is the gold standard for the treatment of end-stage liver disease. A shortage of suitable organs, high costs and surgical complications limit the application of liver transplantation. Mesenchymal stem cell therapy has been considered as a promising alternative approach for end-stage liver disease. Some clinical trials have confirmed the effectiveness of MSC therapy for liver disease, but its application has not been promoted and approved. There are still many issues that should be solved prior to using MSC therapy in clinical applications. The types of liver disease that are most suitable for MSC application should be determined, and the preparation and engraftment of MSCs should be standardized. These may be bottlenecks that limit the use of MSCs. We investigated 22 completed and several ongoing clinical trials to discuss these questions from a clinical perspective. We also discussed the important mechanisms by which MSCs play a therapeutic role in liver disease. Finally, we also proposed novel prospective approaches that can improve the therapeutic effect of MSCs.
#1Mingyang Shao (Sichuan University)H-Index: 3
#2Qing Xu (Sichuan University)H-Index: 5
Last. Hong Bu (Sichuan University)H-Index: 26
view all 12 authors...
Background Using a toxin-induced nonhuman primate model of acute liver failure (ALF), we previously reported that peripheral infusion of human umbilical cord mesenchymal stem cells (hUC-MSCs) strongly suppresses the activation of circulating monocytes and interleukin-6 (IL-6) production, thereby disrupting the development of a cytokine storm and improving the prognosis of monkeys. MSCs are considered to play a therapeutic role under different stresses by adaptively producing specific factors, pr...
33 CitationsSource
#1Changyong Li (WHU: Wuhan University)H-Index: 5
#2Yuting Jin (UCLA: University of California, Los Angeles)H-Index: 2
Last. Bibo Ke (UCLA: University of California, Los Angeles)H-Index: 58
view all 10 authors...
: The Hippo pathway, an evolutionarily conserved protein kinase cascade, tightly regulates cell growth and survival. Activation of yes-associated protein (YAP), a downstream effector of the Hippo pathway, has been shown to modulate tissue inflammation. However, it remains unknown as to whether and how the Hippo-YAP signaling may control NLR family pyrin domain containing 3 (NLRP3) activation in mesenchymal stem cell (MSC)-mediated immune regulation during liver inflammation. In a mouse model of ...
31 CitationsSource
#1Sihyung WangH-Index: 9
#2Ji-Eun KimH-Index: 56
Last. Youngmi JungH-Index: 27
view all 10 authors...
Abstract Liver fibrosis is a major characteristic of liver disease. When the liver is damaged, quiescent hepatic stellate cells (HSCs) transdifferentiate into proliferative myofibroblastic/activated HSCs, which are the main contributors to liver fibrosis. Hence, a strategy for regulating HSC activation is important in the treatment of liver disease. Tumor necrosis factor-inducible gene 6 protein (TSG-6), a cytokine released from mesenchymal stem cells (MSCs), influences MSC stemness. Therefore, ...
6 CitationsSource
#1Eishiro Mizukoshi (Kanazawa University)H-Index: 34
#2Shuichi Kaneko (Kanazawa University)H-Index: 104
Given the success of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cells in clinical settings, the host immune system plays an important role in the recognition and targeting of tumor cells in cancer immunotherapy. As a result, there have been numerous advancements in immune cell therapy using human immune cells. However, recent evidence suggests that one type of immunotherapy alone is not effective for the treatment of cancer, particularly solid tumors. Thus, effective immu...
27 CitationsSource
#1Yusuke Watanabe (Niigata University)H-Index: 6
#2Atsunori Tsuchiya (Niigata University)H-Index: 16
Last. Shuji Terai (Niigata University)H-Index: 34
view all 14 authors...
: We describe a novel therapeutic approach for cirrhosis using mesenchymal stem cells (MSCs) and colony-stimulating factor-1-induced bone marrow-derived macrophages (id-BMMs) and analyze the mechanisms underlying fibrosis improvement and regeneration. Mouse MSCs and id-BMMs were cultured from mouse bone marrow and their interactions analyzed in vitro. MSCs, id-BMMs, and a combination therapy using MSCs and id-BMMs were administered to mice with CCl4 -induced cirrhosis. Fibrosis regression, liver...
38 CitationsSource
#1Jun Li (SJTU: Shanghai Jiao Tong University)H-Index: 39
#2Ya-Hui Wang (SJTU: Shanghai Jiao Tong University)H-Index: 16
Last. Zhigang Zhang (SJTU: Shanghai Jiao Tong University)H-Index: 54
view all 18 authors...
Abstract Background Hepatic fibrosis is caused by chronic liver injury and may progress toward liver cirrhosis, and even hepatocellular carcinoma. However, current treatment is not satisfactory. Therefore, there is a mandate to find novel therapeutic targets to improve therapy, and biomarkers to monitor therapeutic response. Methods Liver fibrosis was induced by carbon tetrachloride (CCl 4 ) or thioacetamide (TAA) in wild type (WT) or CTHRC1 −/− mice, followed by immunofluorescence and immunohis...
25 CitationsSource
#2Ann MullallyH-Index: 27
Last. Rafael KramannH-Index: 36
view all 18 authors...
10 CitationsSource
#1Eun Jung Oh (Kyungpook National University Hospital)H-Index: 2
#1Eun Jung Oh (Kyungpook National University Hospital)H-Index: 6
Last. Byeong-Cheol Ahn (KNU: Kyungpook National University)H-Index: 30
view all 11 authors...
Abstract Mesenchymal stem cell (MSC)-based therapy has emerged as a promising therapeutic strategy for tissue regeneration and repair. In this study, we non-invasively monitored the tracking of MSCs toward burn injury sites using MSCs expressing firefly luciferase (Fluc) gene in living mice, and evaluated the effects of the MSCs at the injury site. Murine MSCs co-expressing Fluc and green fluorescent protein (GFP) were established using a retroviral system (referred to as MSC/Fluc). To evaluate ...
31 CitationsSource
#1Marina GazdicH-Index: 14
Last. Vladislav VolarevicH-Index: 32
view all 11 authors...
: One of the therapeutic options for the treatment of fulminant hepatitis is repopulation of intrahepatic regulatory cells because their pool is significantly reduced during acute liver failure. Although it is known that mesenchymal stem cells (MSCs), which have beneficent effects in the therapy of fulminant hepatitis, may promote expansion of regulatory T cells (Tregs) and regulatory B cells (Bregs), the role of these regulatory cells in MSC-mediated attenuation of acute liver injury is unknown...
20 CitationsSource
#1Li Huang (Xi'an Jiaotong University)H-Index: 1
#2Che Zhang (Xi'an Jiaotong University)H-Index: 7
Last. Haixia Lu (Xi'an Jiaotong University)H-Index: 17
view all 7 authors...
Cerebral palsy (CP) is a common disability which results in permanent chronic motor disability appearing in early childhood. Recently human umbilical cord blood mesenchymal stem cell (hUCB-MSC) infusion has emerged as a promising therapeutic strategy for CP, and the treatment efficacy remains to be confirmed by clinical trials. All 54 patients received basic rehabilitation as a background treatment. The infusion group comprising 27 patients received 4 infusions of hUCB-MSCs (intravenous infusion...
39 CitationsSource
Cited By7
#1Ka Zhang (SYSU: Sun Yat-sen University)H-Index: 5
Last. Xiaoan Yang (SYSU: Sun Yat-sen University)H-Index: 3
view all 8 authors...
BACKGROUND The results of a previous study verified that umbilical cord mesenchymal stem cells (UCMSCs) have good therapeutic effects for the treatment of HBV-related acute-on-chronic liver failure (ACLF) and liver cirrhosis (LC). Nevertheless, it is still unknown whether the effects of UCMSCs are affected by recipient age. METHODS Patients treated with UCMSCs who met the criteria of HBV-related ACLF and liver cirrhosis were identified in this retrospective observational study. Patients were div...
#1Sarah Y Neshat (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 1
#2Victor M Quiroz (JHUSOM: Johns Hopkins University School of Medicine)
Last. Joshua C. Doloff (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 21
view all 5 authors...
The liver is an organ with impressive regenerative potential and has been shown to heal sizable portions after their removal. However, certain diseases can overstimulate its potential to self-heal and cause excessive cellular matrix and collagen buildup. Decompensation of liver fibrosis leads to cirrhosis, a buildup of fibrotic ECM that impedes the liver's ability to efficiently exchange fluid. This review summarizes the complex immunological activities in different liver diseases, and how failu...
#1Da Zou (UQ: University of Queensland)
#2Haolu Wang (UQ: University of Queensland)H-Index: 19
Last. Chun-Xia Zhao (UQ: University of Queensland)H-Index: 25
view all 6 authors...
Abstract null null Liver diseases have become an increasing health burden and account for over 2 million deaths every year globally. Standard therapies including liver transplant and cell therapy offer a promising treatment for liver diseases, but they also suffer limitations such as adverse immune reactions and lack of long-term efficacy. Artificial cells that mimic certain functions of a living cell have emerged as a new strategy to overcome some of the challenges that liver cell therapy faces...
#1Marta Bryk (PAN: Polish Academy of Sciences)H-Index: 3
#2Elżbieta Karnas (Jagiellonian University)H-Index: 9
Last. Katarzyna Starowicz (PAN: Polish Academy of Sciences)H-Index: 30
view all 5 authors...
Mesenchymal stem/stromal cells (MSCs) are multipotent progenitor cells of mesodermal origin. Due to their capacity for self-renewal and differentiation into several cell types, MSCs have been extensively studied in experimental biology and regenerative medicine in recent years. Moreover, MSCs release extracellular vesicles (EVs), which might be partially responsible for their regenerative properties. MSCs regulate several processes in target cells via paracrine signalling, such as immunomodulati...
PURPOSE OF REVIEW Liver transplantation is the gold standard for the treatment of end-stage liver disease. However, a shortage of donor organs, high cost, and surgical complications limit the use of this treatment. Cellular therapies using hepatocytes, hematopoietic stem cells, bone marrow mononuclear cells, and mesenchymal stem cells (MSCs) are being investigated as alternative treatments to liver transplantation. The purpose of this review is to describe studies using MSC transplantation for l...
#1E. A. Suprunenko (MSU: Moscow State University)
#2E. A. Sazonova (MSU: Moscow State University)
Last. A. V. Vasiliev (RAS: Russian Academy of Sciences)H-Index: 10
view all 3 authors...
The review article presents data on extracellular vesicles (EV), bilayer phospholipid membrane structures which are secreted by different cell types and contain proteins, lipids, and nucleic acids. The features of their structure, biogenesis, and mechanisms of interaction with the recipient cell are considered. The properties of extracellular vesicles of embryonic stem cells (ESCs) and their role in the regulation of developmental processes are also considered. Special attention is paid to the v...
#1Tahereh Rostami (Tehran University of Medical Sciences)H-Index: 4
#2Amir Kasaeian (Tehran University of Medical Sciences)H-Index: 76
Last. Ardeshir Ghavamzadeh (Tehran University of Medical Sciences)H-Index: 29
view all 9 authors...
BACKGROUND Hepatic fibrosis is a common complication in transfusion-dependent thalassemia patients. Data on the co-transplantation of mesenchymal stem cells (MSCs) with hematopoietic stem cells (HSCs) in beta-thalassemia major patients are scarce. Therefore, we aimed to evaluate the effect of co-transplantation of bone marrow-derived MSC with HSCs on the liver fibrosis alleviation and transplant outcomes in class III beta-thalassemia major. METHODS Between April 1998 and January 2017, a total of...
#1Maria Tayyab Baig (University of the Punjab)H-Index: 2
#2Hafiz Ghufran (University of the Punjab)H-Index: 1
Last. Sheikh Riazuddin (University of the Punjab)H-Index: 65
view all 6 authors...
Abstract Oxidative microenvironment in fibrotic liver alleviates the efficacious outcome of mesenchymal stem cells (MSCs)-based cell therapy. Recent evidence suggests that pharmacological pretreatment is a rational approach to harness the MSCs with higher therapeutic potential. Here, we investigated whether Vitamin E pretreatment can boost the antifibrotic effects of Wharton’s jelly-derived MSCs (WJMSCs). We used rat liver-derived hepatocytes injured by CCl4 treatment in co-culture system with V...